abstral
Sublingual tablet with fast onset of action for the treatment of breakthrough pain in cancer patients.
Name | Abstral® |
Description | Abstral™ provides fast and effective treatment of breakthrough pain in cancer patients. Abstral™ combines quick-dissolving sublingual tablet technology and the analgesic, fentanyl. |
Active Substance | Fentanyl |
Indication | Breakthrough cancer pain. |
Strengths | 100, 200, 400 μg |
Regulatory Status |
EMA approved June 2008; FDA approved January 2011. |
Business Partner | Kyowa Hakko Kirin Co. Ltd |